Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Active:	No
Cancer Type:	Multiple Myeloma	NCT ID:	NCT02899052
Trial Phases:	Phase II	Protocol IDs:	M15-538 (primary) NCI-2016-01672
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Abbvie
NCI Full Details:	http://clinicaltrials.gov/show/NCT02899052

Summary

A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of
venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with
relapsed or refractory MM and have received 1 to 3 prior lines of therapy.

Part 4 of this study is currently enrolling.

Treatment Sites in Georgia

Emory University Hospital - Atlanta
1364 Clifton Road NE
Atlanta, GA 30322
www.emoryhealthcare.org

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.